The biological target at the heart of the study is a pair of enzymes known as cyclin-dependent kinases 4 and 6, or CDK4 and CDK6. These kinases act as gatekeepers of the cell division cycle, driving the transition from the G1 phase, when cells grow and prepare, into S phase, when DNA is replicated. When the CDK4/6 machinery is dysregulated, cells can escape normal growth controls and proliferate uncontrollably, a hallmark of many malignancies. The importance of these enzymes is underscored by the clinical success of approved CDK4/6 inhibitors such as palbociclib, ribociclib and abemaciclib, which have transformed the treatment landscape for hormone receptor-positive breast cancer and are being explored in other tumor types, including lung cancer.

Yet the existing drugs are not the end of the story. Resistance mechanisms emerge, side effects limit some patients, and clinicians and researchers continue to call for chemically diverse scaffolds, meaning molecules with fundamentally different structural backbones, that can potently inhibit both CDK4 and CDK6 at the same time. Finding such dual inhibitors by traditional high-throughput screening is expensive and slow, which is precisely why the research team turned to computer-aided drug discovery. Their strategy was to build a computational funnel: a wide opening that could swallow an entire chemical library and progressively narrower stages that would discard weak candidates until only the most promising molecules remained.

The first stage of the funnel was ligand-based machine learning. Rather than requiring knowledge of the target protein’s three-dimensional structure, ligand-based models learn from the known activities of compounds that have already been tested. The researchers assembled curated datasets from the ChEMBL database, a public repository of bioactivity data, gathering 265 compounds with measured activity against CDK4 and 402 against CDK6. Each molecule was converted into a numerical representation called an extended-connectivity fingerprint, specifically the ECFP4 format, which encodes the local atomic environments of a molecule in a way that machine learning algorithms can digest. Fingerprint-based descriptors of this kind have become a workhorse of computational chemistry because they capture subtle structural features that often correlate with biological activity.

With the data prepared, the team benchmarked multiple machine learning algorithms to see which could best predict inhibitory potency. The winner was a Bayesian Ridge regressor, a statistical learning method that combines ridge regression with Bayesian regularization, making it robust against overfitting on modestly sized datasets. Trained on the ECFP4 fingerprints, the model achieved cross-validated coefficients of determination, R-squared values, of 0.731 plus or minus 0.022 for CDK4 and 0.721 plus or minus 0.070 for CDK6. In practical terms, this means the model could explain roughly seventy percent of the variance in compound potency from molecular structure alone, a level of predictive accuracy strong enough to make meaningful prioritization decisions. The consistency of performance across both targets was crucial, because the goal was a dual inhibitor, and a model that excelled at one kinase but stumbled on the other would have undermined the entire approach.

The trained machine learning filter was then deployed against a library of 22,823 compounds. The Bayesian Ridge model scored every molecule for its likely activity against CDK4 and CDK6, allowing the researchers to discard the vast majority of the library computationally before any expensive calculation was run. This is where the economics of the approach become compelling: instead of assaying or docking tens of thousands of compounds, the team could concentrate structural modeling resources on the small fraction that the statistical model deemed most promising. The survivors of the machine learning filter then entered the second stage of the funnel, molecular docking against both CDK4 and CDK6.

Docking is a structure-based technique that uses three-dimensional models of the target proteins, typically derived from experimentally determined structures in the Protein Data Bank, to predict how a small molecule physically fits into the binding pocket of the enzyme. The docking calculations, performed at standard precision, evaluated the geometric complementarity and predicted binding energy of each candidate within the ATP-binding sites of both kinases. By requiring candidates to dock well against both CDK4 and CDK6, the researchers enforced dual-target affinity at the structural level, complementing the statistical predictions of the machine learning stage. This dual-target docking refinement whittled the prioritized list down to three candidate hits selected for biochemical evaluation in the laboratory.

The experimental results validated the computational strategy emphatically. Of the three candidates tested, HY-18,623 emerged as a potent dual inhibitor, with a half-maximal inhibitory concentration, IC50, of 3.5 nanomolar against CDK4 and 17.4 nanomolar against CDK6. Values in the low nanomolar range represent the kind of potency typically associated with advanced lead compounds, and achieving it against both kinases simultaneously with a single molecule is exactly what the field has been seeking. The result suggests that the computational funnel did not merely enrich for plausible binders but genuinely identified a molecule with drug-development potential.

To understand why HY-18,623 binds so tightly, the researchers turned to the third pillar of their workflow: molecular dynamics simulations. Docking provides a static snapshot of a predicted binding pose, but proteins and ligands in solution are constantly in motion, and a pose that looks perfect in a single frame may fall apart within nanoseconds. The team ran 200-nanosecond molecular dynamics simulations of the CDK4 and CDK6 complexes with HY-18,623, tracking the stability of the bound state over time using metrics such as root mean square deviation of the atomic positions. The simulations revealed that the compound maintains persistent hydrogen bonds with the so-called hinge residues of both kinases, Val96 in CDK4 and Val101 in CDK6. Hinge-region hydrogen bonding is a canonical anchor of kinase inhibitor binding, and its persistence throughout the simulations indicates a stable, high-affinity binding mode. Binding free energy analyses further quantified the favorable thermodynamics of the interaction, corroborating the experimental potency measurements.

Beyond the specific discovery of HY-18,623, the study offers a template for how modern drug discovery campaigns can be organized. The sequential integration of ligand-based machine learning, structure-based docking and dynamics-based validation creates a hierarchy of evidence, in which each stage interrogates the candidates from a different angle: statistical structure-activity relationships, physical fit within the binding site, and dynamic stability of the complex. The researchers have also made their data publicly available through a GitHub repository, supporting the open-science ethos that is increasingly shaping kinase drug discovery. For a field in which approved CDK4/6 inhibitors have already changed the course of breast cancer treatment, yet resistance and toxicity continue to motivate the search for alternatives, the arrival of a computationally discovered, nanomolar dual inhibitor with a structurally characterized binding mode is a development worth watching. HY-18,623 now stands as a promising lead candidate for further therapeutic development in oncology, and the workflow that produced it as a potentially reusable engine for discovering the next generation of kinase inhibitors.

Subject of Research: Computational virtual screening combining machine learning, docking and molecular dynamics to discover dual CDK4/6 inhibitors for cancer therapy

Article Title: Harnessing machine learning, docking and molecular dynamics for the virtual screening of compounds as CDK4/6 dual inhibitors

Article References: Wang, Y., Fang, L., Liu, Q., Zhang, Z., Xu, C., & Jiang, Y. (2026). Harnessing machine learning, docking and molecular dynamics for the virtual screening of compounds as CDK4/6 dual inhibitors. Molecular Diversity. https://doi.org/10.1007/s11030-026-11716-x

Image Credits: AI Generated

DOI: 10.1007/s11030-026-11716-x

Keywords: CDK4, CDK6, virtual screening, machine learning, molecular docking, molecular dynamics, drug discovery, kinase inhibitors, cancer, ChEMBL, ECFP4 fingerprints, HY-18,623

The concept is deceptively simple, but the engineering is anything but. A classical ADC must remain stable in circulation, recognize its target antigen on the tumor surface, bind specifically, and then be internalized so the payload can enter the lysosome and trigger programmed cell death. Every component matters. The antibody is usually a humanized immunoglobulin G1, chosen for its long serum half-life of roughly two to three weeks and its ability to recruit immune effector mechanisms such as antibody-dependent cell-mediated cytotoxicity. The linker, whether cleavable or non-cleavable, governs when and where the toxin is released. The payload itself must be extraordinarily potent, because only about two percent of an administered ADC dose ever reaches its target antigen, demanding warheads two to six orders of magnitude stronger than standard chemotherapy drugs.

Among the payload classes, tubulin inhibitors such as auristatins and maytansines sabotage cell division, while DNA-damaging agents including topoisomerase I inhibitors, calicheamicins, and pyrrolobenzodiazepines attack the genome directly. A third emerging category uses immunomodulators such as Toll-like receptor and STING agonists to rouse innate immunity. One of the most consequential design features is the bystander effect: membrane-permeable payloads released either inside a tumor cell or in the surrounding microenvironment can diffuse into neighboring cells with low or absent antigen expression, killing tumor cells that would otherwise escape. The drug-to-antibody ratio, determined by the conjugation chemistry, is a delicate balancing act, since lowering it reduces toxicity but also weakens antitumor activity.

No target illustrates the clinical promise of ADCs better than TROP2, a transmembrane glycoprotein highly expressed in roughly 64 percent of lung adenocarcinomas and 75 percent of lung squamous cell carcinomas, where it drives proliferation, invasion, and metastasis. Datopotamab deruxtecan, a humanized anti-TROP2 antibody linked to the topoisomerase I inhibitor DXd, extended median progression-free survival to 4.4 months versus 3.7 months with docetaxel in the phase III TROPION-Lung01 trial, with the benefit concentrated in non-squamous disease, where PFS reached 5.5 months. While overall survival did not reach statistical significance in the overall population, grade three or higher treatment-related adverse events were far less frequent than with chemotherapy. In combination with pembrolizumab in TROPION-Lung02, objective response rates climbed to nearly 55 percent regardless of PD-L1 expression, and pairing the drug with the bispecific antibody rilvegostomig in TROPION-Lung04 produced a confirmed response rate of 57.5 percent with disease control in 95 percent of patients.

Chinese-developed agents are pushing the field further. Sacituzumab tirumotecan, the first domestically developed TROP2 ADC in China, carries a proprietary toxin at a high drug-to-antibody ratio of 7.4 and produced striking results in EGFR-mutant NSCLC: in the OptiTROP-Lung03 trial it nearly tripled progression-free survival compared with docetaxel, at 6.9 versus 2.8 months, with no interstitial lung disease observed. When combined with the immunotherapy tagitanlimab as first-line treatment in OptiTROP-Lung01, the confirmed response rate reached 66.7 percent, and even patients with PD-L1 scores below one percent, who typically respond poorly to immunotherapy alone, achieved a 47.1 percent response rate and 12.4 months of progression-free survival. A phase III trial is now testing this combination against standard chemo-immunotherapy in that difficult population. Sacituzumab govitecan, meanwhile, showed a clinically meaningful survival benefit in patients refractory to prior immunotherapy in the EVOKE-01 study, even though the overall result narrowly missed its statistical threshold.

HER2-targeted ADCs have delivered perhaps the most dramatic transformation. Before their arrival, patients with HER2-mutant NSCLC faced response rates below 15 percent and progression-free survival of only three to four months on standard chemotherapy. Trastuzumab deruxtecan changed that calculus entirely: in DESTINY-Lung02, the 5.4 mg/kg dose produced a confirmed response rate of 50 percent, progression-free survival of 10 months, and median overall survival of 19 months, while the Chinese DESTINY-Lung05 study confirmed a 56.9 percent response rate and 21 months of overall survival, with sustained intracranial control of brain metastases. The next-generation agent trastuzumab rezetecan, known as SHR-A1811, went further still, achieving an unprecedented 73.4 percent response rate and 11.5 months of progression-free survival in heavily pretreated patients, with an interstitial lung disease incidence of just 8.5 percent and a discontinuation rate of only 2.1 percent. The eribulin-based BB-1701 added a 50 percent response rate in a small phase II study, though efficacy in HER2-overexpressing disease remains unresolved.

The target landscape continues to widen. The c-MET-directed ADC SHR-1826 achieved a 39.7 percent response rate and 94.8 percent disease control rate among 58 evaluable NSCLC patients, offering a new strategy against a pathway notorious for driving resistance to EGFR inhibitors. The Nectin-4-targeting SHR-A2102 produced a 43.5 percent response rate in heavily pretreated EGFR-mutant patients, and the integrin beta-6-targeting sigvotatug vedotin reached a 32.5 percent response rate in taxane-naive non-squamous disease, rising to 42.9 percent when combined with pembrolizumab in the first-line setting. Most ambitious of all are bispecific constructs such as izalontamab brengitecan, which targets both EGFR and HER3 simultaneously; in pooled phase I and II analyses of EGFR-mutant NSCLC after TKI failure, it delivered a 48.8 percent response rate, 6.9 months of progression-free survival, and 24.8 months of overall survival, with interstitial lung disease occurring in fewer than one percent of patients, supporting its advance to global phase III registration.

Yet the review is candid about the field’s vulnerabilities. Resistance emerges through multiple routes: tumors downregulate or shed the target antigen, mask it with extracellular matrix proteins, upregulate efflux pumps such as MDR1 and ABCG2 that expel the payload, impair internalization through altered endocytic pathways, or raise lysosomal pH so the linker never releases its cargo. In TROP2-directed therapy, antigen-negative subclones gradually dominate under treatment pressure, while resistance to trastuzumab deruxtecan frequently involves HER2 extracellular domain truncations that preserve kinase activity but eliminate antibody binding. Toxicity remains a serious concern, above all interstitial lung disease, a potentially fatal inflammation of lung tissue associated particularly with topoisomerase I inhibitor payloads, which demands baseline pulmonary testing, vigilant imaging, and prompt corticosteroid intervention. And perhaps most frustratingly, reliable predictive biomarkers are still lacking: conventional immunohistochemistry scores correlate inconsistently with outcomes, and no standardized thresholds exist across platforms, although emerging tools such as circulating tumor DNA analysis and spatial transcriptomics offer hope for smarter patient selection.

The future directions outlined by the authors suggest the field is only beginning to mature. ADCs are moving into earlier disease settings, with the NeoCOAST-2 trial showing that perioperative datopotamab deruxtecan plus durvalumab and chemotherapy achieved a 35.2 percent pathological complete response rate in resectable NSCLC, the best among all tested cohorts. Novel targets including B7-H3, PTK7, and AXL are entering clinical evaluation, while next-generation engineering, from conditionally activated smart linkers and dual-payload constructs to site-specific conjugation platforms and PROTAC-based warheads, aims to widen the therapeutic window. Combination strategies with immune checkpoint inhibitors, EGFR tyrosine kinase inhibitors, and even radiotherapy are under active investigation. What emerges from this sweeping analysis is a clear trajectory: ADCs are transitioning from a promising salvage option to a foundational pillar of NSCLC care, and the coming decade will determine whether rational design, biomarker integration, and combination science can convert their remarkable response rates into durable, personalized cures.

Subject of Research: Antibody–drug conjugate therapy for non-small cell lung cancer

Article Title: Antibody–drug conjugates in non-small cell lung cancer: current landscape and future directions

Article References: Chen, X., Wu, S., Li, F., Yao, C., Liu, Y., & Zhou, G. (2026). Antibody–drug conjugates in non-small cell lung cancer: current landscape and future directions. Holistic Integrative Oncology, 5(1), Article 56. https://doi.org/10.1007/s44178-026-00276-7

Image Credits: AI Generated

DOI: 10.1007/s44178-026-00276-7

Keywords: antibody–drug conjugates, non-small cell lung cancer, TROP2, HER2, c-MET, datopotamab deruxtecan, sacituzumab tirumotecan, trastuzumab deruxtecan, bispecific antibodies, drug resistance, interstitial lung disease, biomarkers

The mechanistic elegance of CAR-T therapy explains much of its success. Researchers harvest T lymphocytes and genetically equip them with synthetic receptors whose extracellular portions, typically single-chain variable fragments, bind specific antigens on malignant cells. When the receptor engages its target, intracellular signaling domains transmit activation signals through immunoreceptor tyrosine-based activation motifs in the CD3ζ chain, recruiting kinases such as LCK and ZAP70 that ignite three core pathways: MAPK, PI3K-Akt, and NF-κB. Costimulatory domains like CD28 or 4-1BB amplify and sustain these signals, and the activated cells then kill through two parallel strategies: perforin and granzyme punch pores in target cells to trigger apoptosis, while death receptor binding via FAS/FASL and TRAIL activates extrinsic cell death. Inflammatory cytokines such as interferon-gamma and tumor necrosis factor-alpha add a broader anti-tumor push. Five successive generations of CAR designs have built on this foundation, from first-generation constructs with only the CD3ζ domain to fifth-generation cells incorporating cytokine receptor signaling modules and logic-gated architectures.

But the therapy’s power comes with a dangerous edge. Cytokine release syndrome, the best-known toxicity, arises when activated CAR-T cells flood the body with pro-inflammatory cytokines including IL-1, IL-6, and interferon-gamma, potentially progressing to multiorgan dysfunction and death. In one study of CD70-directed allogeneic CAR-T therapy, 67 percent of patients experienced CRS, including one grade 4 dose-limiting toxicity. Immune effector cell-associated neurotoxicity syndrome, or ICANS, ranges from mild confusion to severe seizures, and emerging evidence points to cytokine-mediated endothelial activation and blood-brain barrier disruption. A pediatric cohort study documented five cases of acute quadriparesis and paraparesis with demyelinating lesions on MRI and elevated neurofilament light chain in cerebrospinal fluid, but no leukocytic infiltration, revealing a distinct neurotoxicity phenotype. Standard management relies on the IL-6 receptor blocker tocilizumab and corticosteroids, though these agents can suppress the very T cells doing the therapeutic work, a paradox that has spurred engineering of CAR-T cells with IL-6 or interferon-gamma silenced via shRNA.

Solid tumors present an even more formidable fortress. The tumor microenvironment combines physical barriers, including dense extracellular matrix and disorganized vasculature that impairs T cell extravasation, with an immunosuppressive cellular landscape of myeloid-derived suppressor cells, regulatory T cells, and M2-polarized macrophages. Hypoxia, acidosis, and metabolic competition further drain CAR-T cell fitness. Tumors also deploy cell-intrinsic defenses: spatial and temporal heterogeneity in antigen expression, confirmed by single-cell RNA sequencing across tumor subregions, allows antigen-negative subclones to escape under therapeutic pressure, while checkpoint ligands such as PD-L1 and B7-H3 drive T cell exhaustion. On-target off-tumor toxicity compounds the danger, since many solid tumor antigens also appear on healthy tissue. Researchers are responding with affinity-tuned binders, logic-gated and dual CAR designs, and synthetic biology circuits that demand multiple simultaneous signals before the cells attack, aiming for precision that spares normal tissue.

T cell exhaustion itself has become a molecular battleground. Transcription factors TOX, TOX2, and NR4A family members program the exhausted state, regulated by NFAT acting even without its AP-1 partner. Exhausted cells upregulate inhibitory receptors including PD-1, TIM3, and LAG-3, suffer impaired mitochondrial function and suppressed glycolysis, and lose proliferative capacity. Tumor-derived extracellular vesicles can push CAR-T cells into this dysfunctional state by inducing supraphysiologic inflammation. Countermeasures are emerging: overexpression of c-Jun confers exhaustion resistance and enhances expansion, inhibition of sphingosine 1-phosphate receptor 3 remodels the microenvironment and improves infiltration, and MEK inhibitors downregulate c-Fos and JunB to prevent exhaustion-driven differentiation. These interventions, combined with checkpoint inhibitors, aim to keep engineered cells in a persistent, cytotoxic, stem-like state.

Engineering innovation is accelerating on every front. Charge density modulation of the CAR antigen-binding domain optimizes tonic signaling and reduces spontaneous activation, while endogenous signaling molecule activating CARs recruit native signaling molecules through their transmembrane domains, showing promise against triple-negative breast cancer with less cytokine release than conventional designs. Armored CAR-T cells secrete payloads directly into the tumor: IL-15 and CCL19-secreting cells show enhanced efficacy in glioblastoma models, Serpin B9-armored cells resist granzyme B-mediated fratricide, FOXP3-coexpressing cells acquire stem-like durability, and TIM-3-Fc decoy secretion improves CD19 CAR-T therapy in B-ALL by neutralizing galectin-9. Synthetic Notch receptors enable conditional CAR expression only when cells encounter tumor vascular markers like P-selectin, creating microenvironment-actuated T cells that improve selectivity while preserving potency. Multivalent ELECTRIC CARs targeting KIT, MPL, and FLT3 simultaneously offer a non-genotoxic conditioning strategy for leukemia, and tri-functional M10 cells designed against HIV-1 combine cytotoxicity, viral neutralization, and B-cell follicle homing.

Perhaps the most disruptive shift involves manufacturing. Autologous CAR-T production remains slow, complex, and costly, often exceeding $400,000 per patient, with a median 108 days from consultation to infusion in community networks and 41 percent of patients unable to access timely therapy. Universal off-the-shelf products derived from healthy donors promise immediate availability and consistent quality, with CRISPR/Cas9 knockout of TCR and HLA genes mitigating graft-versus-host disease and host-versus-graft rejection. Mucosal-associated invariant T cells, which do not mediate alloreactivity, offer an allogeneic source requiring minimal genetic modification. Even more radical is in vivo CAR-T generation: delivering viral vectors or targeted lipid nanoparticles encoding the CAR construct directly into the patient, reprogramming circulating T cells in situ and eliminating ex vivo manipulation entirely. Recent work has demonstrated in vivo generation of functional CAR-T cells for cancer and autoimmune disease, though vector immunity, insertional mutagenesis risk, and dosing control remain unsolved.

Clinical results are now extending well beyond blood cancers. Claudin 18.2-targeted CAR-T cells achieved a 38.8 percent overall response rate and 91.8 percent disease control rate in gastrointestinal cancers, with 96.9 percent of patients experiencing only grade 1-2 CRS and no treatment-related deaths. GD2-directed cells delivered a 63 percent response rate in high-risk neuroblastoma with three-year overall survival reaching 60 percent, while CD70-targeted allogeneic cells produced an 81.3 percent disease control rate in clear cell renal cell carcinoma. In multiple myeloma, the dual BCMA/CD19 construct GC012F achieved a 100 percent response rate with 95.5 percent complete remission. Most strikingly, CD19 CAR-T therapy is rewriting the playbook for autoimmune disease: a German cohort achieved 100 percent drug-free remission in 15 refractory autoimmune patients, and universal CD19 CAR-T cells reversed skin fibrosis in systemic sclerosis patients, with one regaining finger mobility within days of infusion, challenging the assumption that fibrotic damage is irreversible.

The review’s authors frame the future around three strategic priorities: optimized CAR design, combination therapies, and scalable manufacturing. Gene editing with CRISPR enzymes such as PcoCas12a can knock out negative regulators like DGKα to boost anti-tumor function, while deletion of NR4A factors, CTLA-4, or the adenosine A2A receptor enhances persistence in hypoxic tumor niches. Combinations with pembrolizumab, ibrutinib, oncolytic viruses, and STING agonists aim to convert immunologically cold tumors into hot ones, and automated bioreactors, non-viral gene transfer, and point-of-care manufacturing promise to slash costs and timelines. Applications in infectious disease, where bNAb-derived CAR-T cells have reduced HIV reservoirs, and in fibrosis and senescence, where senolytic CAR-T cells target age-related dysfunction, suggest the platform may ultimately transcend oncology altogether. What began as a last-resort therapy for dying leukemia patients is evolving into a versatile system of precision immune reprogramming, one whose full scope researchers are only beginning to map.

Subject of Research: Advances, challenges, and clinical breakthroughs of CAR-T cell therapy in refractory cancers and beyond

Article Title: Advances in CAR-T cell therapy for refractory diseases: challenges, innovations, clinical breakthroughs, and future prospects

Article References: Liao, Q., Mao, Y., Feng, M., Zheng, N., Ding, X., Zhang, X., Wang, Z., & Xu, J. (2025). Advances in CAR-T cell therapy for refractory diseases: challenges, innovations, clinical breakthroughs, and future prospects. Clinical Cancer Bulletin, 4(1), Article 21. https://doi.org/10.1007/s44272-025-00050-2

Image Credits: AI Generated

DOI: 10.1007/s44272-025-00050-2

Keywords: CAR-T cell therapy, immunotherapy, solid tumors, cytokine release syndrome, CRISPR gene editing, autoimmune disease, hematological malignancies, tumor microenvironment, off-the-shelf CAR-T, in vivo CAR-T, T cell exhaustion, cell therapy manufacturing

The ubiquitin–proteasome system is the cell’s principal machinery for controlled protein destruction. Small ubiquitin tags are attached to target proteins through an enzymatic cascade involving activating enzymes, conjugating enzymes and ligases, and proteins carrying specific ubiquitin chains are recognized and degraded by the proteasome, a barrel-shaped proteolytic complex. Because the system governs the abundance of virtually every regulatory protein in the cell, including tumor suppressors, cell-cycle drivers and signaling components, it has long been considered a rich source of therapeutic targets. The clinical success of proteasome inhibitors in multiple myeloma, and more recently the explosive growth of targeted protein degrader technologies, have confirmed that manipulating protein turnover can be a powerful anti-cancer strategy.

Deubiquitinases, or DUBs, sit at the opposite end of this pathway. Rather than attaching ubiquitin, these proteases remove it, cleaving ubiquitin chains from substrates or editing the architecture of the chains themselves. In doing so, DUBs stabilize proteins that would otherwise be destroyed, fine-tune signaling complexes and recycle ubiquitin for reuse. The human genome encodes roughly one hundred DUBs, distributed across several mechanistically distinct families, including cysteine proteases of the USP, UCH, OTU and MJD classes and metalloproteases of the JAMM family. Their activities touch nearly every cellular process, and a growing body of evidence shows that many DUBs are dysregulated in cancer, where they act as oncogenes or tumor suppressors depending on the context.

The review’s central thesis is that DUBs are deeply intertwined with KRAS biology, and that this connection creates therapeutic openings that conventional approaches have overlooked. KRAS operates as a molecular switch, cycling between an active, GTP-bound state and an inactive, GDP-bound state, and transmitting signals downstream through the RAF–MEK–ERK and PI3K–AKT pathways. Each stage of this circuit is buffered by ubiquitin-dependent regulation. Ubiquitin ligases such as the CUL3 complex, which recognizes active KRAS through the adaptor protein calcoco-2, can ubiquitinate KRAS and promote its degradation, acting as a built-in brake on signaling. DUBs that remove ubiquitin from KRAS or from components of its downstream pathways effectively remove that brake, amplifying and prolonging the oncogenic signal. Conversely, inhibiting the right DUB could restore the degradation of mutant KRAS or sensitize tumor cells to existing inhibitors.

Several individual DUBs have emerged as particularly compelling nodes in this network. The USP family member USP11, for example, has been reported to stabilize KRAS by removing its ubiquitin marks, thereby sustaining ERK signaling in KRAS-mutant cells. USP21 and USP22 have similarly been implicated in supporting KRAS-driven transcriptional programs, partly through their effects on chromatin regulators and signaling intermediates. On the downstream side, DUBs such as USP9X, USP5 and CYLD regulate the stability of RAF, MEK and ERK pathway components as well as NF-kappaB signaling, shaping both the intensity of the oncogenic output and the inflammatory milieu of the tumor microenvironment. Because these enzymes act at multiple points in the circuit, they offer a way to modulate KRAS signaling even when direct inhibition of the protein itself is technically or clinically difficult.

This matters enormously for the translational landscape. The G12C inhibitors sotorasib and adagrasib demonstrated that covalent drugs can reach mutant KRAS in the recessed pocket of its switch-II region, yet their impact is limited to the roughly one in eight KRAS-mutant tumors that carry the G12C alteration, and resistance through pathway reactivation, tissue plasticity and drug-tolerant persister cells develops within months. Approaches that work through protein turnover are intrinsically broader. A DUB inhibitor, or a degrader built on DUB biology, would not need a druggable pocket on KRAS itself; it would only need to shift the balance of the degradation machinery. The review highlights this as a route toward tumors carrying non-G12C mutations such as G12D, G12V and Q61, which together account for the majority of KRAS-driven cancers and remain without approved targeted therapies.

The therapeutic logic also extends to combination strategies. Preclinical studies indicate that degrading or destabilizing KRAS, whether through ligase recruitment or through DUB inhibition, can cooperate with upstream and downstream blockade, for instance pairing proteasome-directed approaches with SHP2 inhibitors, MEK inhibitors or ERK inhibitors to collapse the adaptive signaling networks that tumors deploy under treatment pressure. In resistant tumors where KRAS amplification or bypass signaling restores ERK output, lowering the total pool of KRAS protein could re-sensitize cells to doses of pathway inhibitors that are otherwise survivable. The review frames DUB targeting as a complementary pillar to the degrader boom: while molecular glue compounds and PROTACs recruit ubiquitin ligases to tag targets for destruction, DUB inhibitors would work by removing the enzymes that protect oncogenic proteins from destruction.

The challenges, however, are substantial, and the review is candid about them. DUBs are proteases, and designing selective inhibitors for cysteine protease active sites has proven difficult, with many early compounds suffering from broad reactivity and poor pharmacology. Redundancy is a second obstacle: multiple DUBs can often compensate for one another, meaning that single-agent inhibition may produce modest effects unless the dominant node in a given tumor is correctly identified. There is also the problem of context. The same DUB can act as an oncogene in one cancer and a tumor suppressor in another, so patient stratification and biomarker development will be essential. Finally, because the ubiquitin system regulates a vast range of non-cancerous processes, including immune signaling and DNA repair, systemic toxicity must be carefully evaluated.

To navigate these difficulties, the review outlines several priorities for the field. Better structural biology and cryo-electron microscopy of DUB-substrate complexes could reveal allosteric and protein-protein interaction surfaces that are more drug-friendly than catalytic sites. Proteomic approaches that map the ubiquitin landscape of KRAS-mutant tumors, increasingly accessible through ubiquitin-remnant mass spectrometry, could identify which DUBs are genuinely rate-limiting in which genetic backgrounds. And emerging chemical modalities, including covalent fragments targeting non-catalytic cysteines, targeted protein degraders and PROTAC-inspired molecules that eliminate DUBs themselves rather than merely inhibiting them, may open doors that classical enzyme inhibitors could not. The authors argue that systematic functional genomics, using CRISPR screens in panels of KRAS-mutant cell lines, will be key to converting the growing catalog of DUB-KRAS interactions into a validated target hierarchy.

The significance of this synthesis lies in its reframing of a familiar problem. Rather than treating KRAS as a target to be occupied, it treats the KRAS-mutant cell as a network whose protein economy can be rewired. The ubiquitin–proteasome system provides the levers, and deubiquitinases, once obscure players in basic cell biology, are now positioned as actionable points of intervention in some of medicine’s most intractable cancers. If the chemical and biological hurdles can be overcome, the coming years could see DUB-directed therapies enter clinical trials for pancreatic, lung and colorectal cancers, offering new hope to patients whose tumors have eluded the first generation of KRAS drugs.

Subject of Research: Therapeutic targeting of deubiquitinases in the ubiquitin–proteasome system to treat KRAS-driven cancers.

Article Title: Rewiring KRAS-driven cancers through the ubiquitin–proteasome system: therapeutic opportunities with a focus on deubiquitinase

Article References: Lee, Y., Hwang, S., Shin, H., Choi, K., Seo, S., Kim, H., Yang, J. S., Kim, Y. J., Kim, Y.-M., & Song, E. J. (2026). Rewiring KRAS-driven cancers through the ubiquitin–proteasome system: therapeutic opportunities with a focus on deubiquitinase. Experimental & Molecular Medicine. https://doi.org/10.1038/s12276-026-01837-6

Image Credits: AI Generated

DOI: 10.1038/s12276-026-01837-6

Keywords: KRAS, deubiquitinase, ubiquitin-proteasome system, targeted cancer therapy, protein degradation, RAS signaling, proteasome inhibitors, oncology, USP family, drug resistance, Rewiring, KRAS-driven

The researchers set out to close a major gap in kinome pharmacology. Protein kinases—the 518 enzymes that phosphorylate most human proteins and orchestrate nearly every cellular process—are not merely catalytic cores. Beyond their conserved kinase domains, they carry additional domains that mediate autoinhibition, subcellular localization, and complex formation. Autoinhibitory domains (AIDs) typically keep kinases dormant by docking onto the kinase domain and masking the ATP-binding site, blocking both enzymatic activity and substrate interactions until an activating signal relieves this restraint. Classical structural methods struggle to characterize these domains because many AIDs are intrinsically disordered or connected to the catalytic core through flexible linkers, and most structural studies rely on truncated, purified recombinant proteins that lack the physiological post-translational modifications and binding partners essential for correct function. Whether ATP-competitive inhibitors, which stabilize the active DFG-in conformation of the kinase domain, also force structural changes at the AID remained a poorly explored dark space.

To address this, the team developed a multimodal proteomics strategy combining three complementary mass spectrometry-based approaches. The first, AP-LiP-MS, applies limited proteolysis coupled to mass spectrometry on affinity-purified samples: kinases are purified from human cells under native conditions, treated with an inhibitor, and then exposed to proteinase K, which preferentially cleaves accessible and flexible regions. Changes in the resulting conformation-specific peptide fragments reveal structural shifts with high sequence coverage while preserving the native cellular context. This structural readout was paired with contextual proteomics—affinity purification mass spectrometry (AP-MS) to measure complex formation and in vivo proximity labeling using the miniTurbo biotin ligase to map the kinase’s biochemical neighborhood in living cells. The approach was first benchmarked on the kinase DCLK1, where known X-ray crystal structures of the autoinhibited and inhibitor-bound states confirmed that AP-LiP-MS faithfully detects the anticipated structural rearrangements.

Applying the workflow to three disease-associated kinases with well-characterized ATP-competitive inhibitors—CAMKK2 targeted by SGC-CAMKK2-1, CHEK1 targeted by rabusertib, and PRKCA targeted by Gö 6983—the researchers found a striking common theme. In every case, inhibitor binding produced structural changes precisely at the autoinhibitory domain, with increased proteinase K susceptibility indicating that the AID becomes more solvent-exposed. This is consistent with the AID dissociating from the kinase domain, driving the inhibited enzyme into an open, active-like conformation that mimics the structural unlocking that occurs during normal kinase activation. Notably, a structurally similar negative control compound that does not bind CAMKK2 induced neither structural nor interaction changes, confirming the specificity of the observations. For PRKCA, structural alterations extended into the membrane-binding C2 domain, specifically at a short regulatory segment associated with autoinhibition, hinting that multiple domain-domain interactions are disrupted by drug binding.

The consequences of these conformational shifts proved to be as diverse as they were unexpected. For CAMKK2, the inhibitor stabilized a complex between CAMKK2 and PRKAA1, the catalytic subunit of the AMPK energy-sensing complex. Catalytically inactive and autonomously active CAMKK2 mutants responded to the drug with the same interaction pattern, demonstrating that the effect depends on the conformational change rather than on catalytic inhibition. Structural modeling with AlphaFold3 suggested that the activation-relevant T183 residue of PRKAA1 becomes buried within the predicted CAMKK2–PRKAA1 interface. Functional experiments confirmed the implication: in glucose-starved cells, SGC-CAMKK2-1 reduced T183 phosphorylation of PRKAA1 by upstream kinases such as LKB1, and this suppression was rescued when CAMKK2 was depleted by siRNA. In other words, the inhibited kinase acts as a physical shield that sequesters AMPK and blocks its activation through an entirely non-catalytic, scaffolding mechanism—potentially shutting down both the calcium-dependent and energy-stress branches of AMPK signaling simultaneously.

Strikingly, a disease-associated CAMKK2 variant, the R311C mutation found in a patient with bipolar disorder, completely abolished the inhibitor-induced interaction with PRKAA1. Because R311 faces the predicted interaction interface while the neighboring catalytic residue D312 lies outside it, the finding offers the first mechanistic clue for how this genetic variant may uncouple the CAMKK2–AMPK signaling axis in patients, and it underscores that drug responses can depend critically on the specific disease variant a patient carries—a consideration for personalized medicine.

The second model kinase, CHEK1, revealed a different flavor of paradox. Rabusertib remodeled CHEK1’s interactions with numerous DNA-damage response proteins, increasing binding to 14-3-3 proteins, the deubiquitylating enzyme USP7, PCNA, and MCM replication licensing factors, and elevating phosphorylation at the ATR-targeted S317 site—changes mirroring those seen during genuine DNA damage-induced activation. The single interactor that dissociated was CLPB, a mitochondrial protein previously identified in multiple studies as a CHEK1 partner. CLPB dissociation occurred in both wild-type and catalytically inactive CHEK1 but not in a constitutively open mutant, again implicating the conformational rather than catalytic consequence of inhibition. Because CLPB loss is known to cause mitochondrial fragmentation, the researchers examined mitochondrial morphology by super-resolution microscopy. Rabusertib treatment significantly increased mitochondrial fragmentation, an effect that persisted even when the canonical CDK1–DRP1 fragmentation pathway was blocked with the CDK1 inhibitor RO-3306, and that could not be reproduced by DNA damage alone. While a direct causal link between CHEK1–CLPB dissociation and fragmentation remains to be established, the data suggest that CHEK1 inhibition may disrupt mitochondrial proteostasis through a mechanism independent of the drug’s intended catalytic target.

The third model, PRKCA, demonstrated how inhibitor-induced structural changes can redirect a kinase within the cell. Upon Gö 6983 binding, proximity labeling revealed a rapid shift of PRKCA toward membrane-associated proteins at cell junctions, including tight junction, adherens junction, and desmosome components, as well as the known interactor integrin beta-1. Calcium imaging ruled out changes in intracellular calcium as the driver, and a dose-response experiment showed that these junctional proximity changes occurred at significantly lower drug concentrations than other effects, consistent with a specific on-target mechanism. Catalytically inactive and constitutively active PRKCA mutants responded identically, confirming the phenotype is independent of catalytic inhibition. Live-cell imaging of EGFP-tagged PRKCA captured the kinase relocating to the cell periphery—particularly cell-cell contact sites—within eight minutes of drug addition. The researchers propose that Gö 6983 binding opens the C2 domain, exposing a lysine cluster that can bind the junctional lipid PIP2, thereby recruiting the inhibited kinase to membranes through a calcium-independent route.

Taken together, the study establishes the ATP-binding site as a major organizing center of kinase conformation and interaction, and suggests that inhibitor-induced non-catalytic gain-of-function is likely far more prevalent among kinases with autoinhibitory domains than currently appreciated. The authors point to existing examples such as the JAK2 inhibitor ruxolitinib, which paradoxically primes JAK2 hyperphosphorylation and contributes to side effects after drug withdrawal, and BRAF inhibitors that allosterically promote RAF dimerization and MAPK activation, as evidence that such mechanisms already matter clinically. Because many AID-mediated effects would be missed by conventional target engagement assays focused on catalytic kinetics, the authors advocate for systematic multimodal proteomic profiling of both wild-type and disease-mutant kinases during early drug development. The combination of structural and contextual proteomics is not restricted to kinases and could extend to targets lacking catalytic activity altogether. By mapping inhibitor-modulated conformational and interactome landscapes early, researchers hope to detect unexpected liabilities before they surface in the clinic, ultimately guiding the design of safer and more effective kinase-targeted therapeutics.

Subject of Research: Inhibitor-induced displacement of kinase autoinhibitory domains driving non-catalytic drug effects

Article Title: Paradoxical non-catalytic kinase functions are driven by inhibitor-induced displacement of autoinhibitory domains

Article References: Reber, V., Keller, S., Loosli, S. A., Arima, Y., Kleele, T., Picotti, P., & Gstaiger, M. (2026). Paradoxical non-catalytic kinase functions are driven by inhibitor-induced displacement of autoinhibitory domains. Molecular Systems Biology, 22(9), 1474-1500. https://doi.org/10.1038/s44320-026-00229-2

Image Credits: AI Generated

DOI: 10.1038/s44320-026-00229-2

Keywords: kinase inhibitors, autoinhibitory domains, proteomics, protein-protein interactions, CAMKK2, CHEK1, PRKCA, AMPK, mitochondrial fragmentation, drug mechanisms, conformational change, Molecular Systems Biology

The chemistry behind the new agent is as intriguing as its biological performance. Rather than simply tweaking the fluorouracil scaffold, the team constructed a library of fourteen compounds in which the 5-FU core was conjugated to phosphonium groups, positively charged chemical motifs that are drawn to the negative electrical potential that exists across the inner membrane of mitochondria, the energy factories of cells. This design strategy, sometimes exploited in mitochondrial-targeting drugs, was intended to ferry the cytotoxic payload more effectively into the cellular compartments where pro-survival signaling is orchestrated. When the researchers screened their library against prostate cancer cells, one candidate separated decisively from the pack. EB-18 displayed sub-micromolar cytotoxicity against both PC-3 cells, which lack the androgen receptor, and C4-2 cells, a model of castration-resistant prostate cancer in which the androgen receptor remains active. That dual potency matters, because castration-resistant prostate cancer that no longer responds to androgen-deprivation therapy represents one of the most stubborn clinical challenges in urologic oncology.

Prostate cancer was only the beginning. The investigators extended their testing across a panel of malignant solid-tumor cell lines from other organs, and EB-18 retained its killing power, supporting the team’s description of the compound as a candidate for pan-cancer application. In laboratory assays designed to mimic key stages of tumor aggression, the molecule inhibited cell proliferation, impaired cell migration, and suppressed the growth of three-dimensional tumor spheroids, which are considered more faithful stand-ins for real tumors than flat layers of cells. When the researchers peered into the treated cells, they found the hallmarks of a coordinated self-destruction program: perturbation of the cell cycle, the tightly regulated sequence of events by which cells duplicate their DNA and divide, followed by apoptosis, the programmed cell death that cancer cells so often evade.

The mechanistic story that emerged from these studies is layered and, in several respects, unexpected for a 5-FU descendant. Classic 5-FU works largely by masquerading as a normal DNA and RNA building block, poisoning nucleotide synthesis. EB-18, by contrast, appears to attack cancer cells on multiple fronts simultaneously. The compound disrupted survival signaling associated with HSP27, a heat shock protein that tumor cells rely on to buffer stress and resist chemotherapy-induced death. HSP27 has long interested oncologists precisely because elevated levels of the protein correlate with poor treatment outcomes in several cancers; indeed, a corresponding author of the new study holds patents on an antisense inhibitor of HSP27 previously developed for clinical use. EB-18’s ability to interfere with this protective machinery at the small-molecule level rather than through genetic silencing represents a different route to the same therapeutic vulnerability.

The compound’s second major target proved equally consequential. EB-18 promoted the ubiquitination of DDX5, a DNA helicase protein involved in transcription and cell proliferation, tagging it for destruction by the proteasome, the cellular waste-disposal system that shreds proteins marked with ubiquitin chains. Loss of DDX5 crippled downstream AKT/mTOR signaling, a central growth pathway that tumors co-opt to sustain unrelenting proliferation. In parallel, the researchers observed that EB-18 increased levels of γ-H2AX, a molecular beacon that flags double-strand breaks in DNA, while reducing expression of Ku70 and Ku80, proteins that help repair precisely those breaks. In other words, the drug appears to inflict severe DNA damage while simultaneously dismantling the repair crews that would normally rescue the cell, a one-two combination that pushes malignant cells past the point of no return. In androgen receptor-positive C4-2 cells, EB-18 additionally drove down expression of the androgen receptor itself, striking at the engine of castration-resistant disease.

What elevates the study beyond conventional cell-culture pharmacology is the rigor of its disease models. The team tested EB-18 in patient-derived organoids, miniature tumors grown from tissue donated by people with prostate cancer, which preserve much of the cellular heterogeneity and drug responsiveness of the original malignancies. The compound retained its activity in these organoids and, critically, in multidrug-resistant castration-resistant prostate cancer cells, the kind of refractory disease that clinicians most dread encountering. Patient tissue for this work was obtained through the Biological Resource Centre of the Marseille Public Hospital System with written informed consent, under protocols certified to international biobanking standards, lending the findings a translational credibility that laboratory models alone cannot provide.

The final preclinical proof came from living animals. In mouse xenografts bearing PC-3 prostate tumors, treatment with EB-18 significantly inhibited tumor growth, confirming that the compound’s cellular effects translate into tangible anti-tumor activity in vivo. According to the authors, EB-18 demonstrated superior anticancer activity compared with 5-FU itself and with clinically used chemotherapies including docetaxel, cabazitaxel, and mitoxantrone across the preclinical models examined. That comparison is striking, because docetaxel and cabazitaxel are the current workhorses of chemotherapy for metastatic castration-resistant prostate cancer, and both eventually fail as resistance develops. A single small molecule capable of matching or exceeding the performance of these agents, while retaining efficacy in multidrug-resistant cells, would represent a meaningful expansion of the therapeutic arsenal.

The research was carried out by a multidisciplinary team spanning several French institutions, including CNRS and INSERM research units in Marseille and the Institut Pasteur in Paris, and was supported by INSERM, the Ligue Nationale Contre Le Cancer, ITMO Cancer, and the Amidex Foundation, with additional funding under the France 2030 investment plan. The work emerges from a laboratory with a long-standing interest in HSP27 biology and its exploitation in cancer therapy, and the authors note commercial interests, including co-founding of a biotechnology company focused on precision medicine and nucleic acid therapeutics, alongside patent filings related to HSP27 inhibition. Such entanglements are common in translational oncology and underscore how close the scientists consider this molecule to be to real-world relevance, though they also signal the need for independent validation.

Considerable distance remains between a promising preclinical candidate and an approved medicine. EB-18 has not yet been tested in humans, and the authors themselves frame their findings as a rationale for further pharmacological, mechanistic, and translational evaluation rather than as a treatment ready for the clinic. Toxicology, pharmacokinetics, dosing, formulation, and safety profiling all lie ahead, along with the unpredictable attrition that claims most experimental drugs. Nevertheless, the study offers a compelling proof of concept: that a sixty-year-old chemotherapy scaffold, creatively re-engineered with mitochondrial-targeting chemistry and aimed at resistance-driving pathways such as HSP27 signaling, DDX5 degradation, and the DNA damage response, can be reborn as a broader, harder-to-defeat weapon. If subsequent development sustains the momentum reported here, EB-18 could eventually give oncologists a genuinely new option against tumors that have exhausted every currently available line of defense.

Subject of Research: A novel phosphonium-substituted 5-fluorouracil derivative, EB-18, developed as a pan-cancer chemotherapy candidate that improves antitumor efficacy and overcomes therapy resistance.

Article Title: A novel 5-FU derivative chemotherapy: a promising pan-cancer treatment to improve antitumor efficacy and overcome therapy resistance

Article References: Duong, Q. H., Khusnutdinova, E., Le, T. K., Hu, Y., Tran, T. T., Nail, V., Balasse, L., Dinh, T. D., Phan, T. T. U., Borie-Guichot, M., Baboudjian, M., Garzino, F., Guillet, B., Taïeb, D., Camplo, M., & Rocchi, P. (2026). A novel 5-FU derivative chemotherapy: a promising pan-cancer treatment to improve antitumor efficacy and overcome therapy resistance. Journal of Experimental & Clinical Cancer Research. https://doi.org/10.1186/s13046-026-03826-z

Image Credits: AI Generated

DOI: 10.1186/s13046-026-03826-z

Keywords: 5-fluorouracil, EB-18, chemotherapy, castration-resistant prostate cancer, drug resistance, HSP27, DDX5, AKT/mTOR signaling, DNA damage response, apoptosis, patient-derived organoids, xenograft models

The story of this breakthrough begins with the RAS family of proteins, the quintessential molecular villains of pancreatic cancer. RAS mutations are present in more than 90 percent of pancreatic ductal adenocarcinoma cases, with the KRAS G12D, G12V, and G12R subtypes being the most frequent. For roughly four decades, these proteins were branded “undruggable.” The problem was structural: RAS proteins present a smooth, near-spherical surface lacking the classical deep pockets that small-molecule drugs typically exploit for binding. The arrival of KRAS G12C inhibitors cracked that impasse, proving that a chemical handle could be found on this notoriously slippery target. Yet the victory was narrow. G12C mutations account for only 1 to 2 percent of pancreatic cancers, limiting the clinical reach of those agents to a vanishingly small fraction of the patient population that desperately needs them.

Daraxonrasib, developed from the investigational compound RMC-6236, takes a fundamentally different pharmacological route. Rather than locking onto a single mutant allele in its inactive, GDP-bound state, the drug employs what its developers call RAS(ON) multi-selective inhibition. It is a non-covalent tri-complex inhibitor: the molecule first binds intracellular cyclophilin A to form a binary complex, and that complex then selectively attaches to the active, GTP-bound conformation of RAS proteins. Because it targets the switched-on state that drives cancer signaling, it can simultaneously cover a broad spectrum of RAS isoforms — KRAS, NRAS, and HRAS — and mutant alleles including G12D, G12V, G12R, G13, and Q61. This breadth transforms the calculus of RAS therapy. A strategy that once addressed a sliver of patients now reaches more than 90 percent of those with pancreatic cancer, marking a fundamental transition from allele-specific inhibition to broad-spectrum suppression of the RAS signaling engine.

The clinical evidence underpinning this shift has accumulated with unusual speed and rigor. In the phase I/II trial reported by Wolpin and colleagues, 168 patients with previously treated advanced RAS-mutant pancreatic cancer were enrolled. Among those with RAS G12 mutations receiving the 300-milligram dose as second-line therapy, the objective response rate reached 35 percent, the disease control rate was a striking 92 percent, and median duration of response, progression-free survival, and overall survival were 8.2, 8.5, and 13.1 months, respectively. Across all RAS-mutant patients carrying G12, G13, or Q61 alterations, the response rate was 29 percent with a median overall survival of 15.6 months. Grade 3 or higher treatment-related adverse events occurred in 30 percent of patients, predominantly rash and gastrointestinal toxicities, both of which proved manageable with standard clinical interventions.

Building on that foundation, O’Reilly and colleagues advanced daraxonrasib into the phase III RASolute 302 trial, an open-label randomized controlled study of 500 patients with previously treated metastatic pancreatic cancer, 91.8 percent of whom harbored RAS G12 mutations. The results were decisive. In the RAS G12 population, daraxonrasib achieved a median overall survival of 13.2 months compared with 6.6 months for chemotherapy, corresponding to a hazard ratio of 0.40 with a P value below 0.001. Median progression-free survival doubled from 3.5 to 7.3 months, again with a hazard ratio of 0.45. The intention-to-treat analysis yielded nearly identical figures — 13.2 versus 6.7 months — underscoring the robustness of the effect. Notably, the response rate in the daraxonrasib arm was 31.6 percent, roughly triple the 11.2 percent seen with chemotherapy. Patient-reported quality of life and time to pain deterioration, metrics that carry enormous weight in a disease defined by debilitation, were also significantly improved.

The safety profile added further weight to the case. Grade 3 or higher treatment-related adverse events occurred in 43.6 percent of patients receiving daraxonrasib, lower than the 57.5 percent observed with chemotherapy. Treatment discontinuation due to adverse events was just 1.2 percent with the targeted agent compared with 11.2 percent with chemotherapy. Rash and diarrhea were the most common side effects, but the majority were grade 1 to 2 and could be managed with routine clinical measures. For a drug that intervenes directly on what was long considered the most intractable target in oncology, this tolerability profile represents a remarkable pharmacological achievement.

Placed in historical context, the magnitude of these results becomes even more apparent. A median overall survival of 13.2 months, achieved in the second-line setting, surpasses the historic benchmark of FOLFIRINOX as a first-line regimen, which delivered 11.1 months. The 42-second standing ovation that greeted the data at the ASCO 2026 plenary session reflected not mere numerical progress but a genuine paradigm shift in treatment strategy. The implications extend to surgical oncology as well: approximately 39 percent of patients in the phase I/II study had previously undergone pancreatic resection, a population for whom effective second-line options have long been lacking. Daraxonrasib now offers these patients a meaningful alternative, and given its robust efficacy in advanced disease, investigators argue that moving the drug into the adjuvant or neoadjuvant setting deserves serious consideration.

Still, a measured perspective is warranted. Both published studies were industry-sponsored, and independent real-world validation remains essential before the results are universally adopted into practice. Although rash and gastrointestinal toxicities were predominantly low-grade, standardized management protocols will need to be established as clinical use expands beyond the controlled environment of a trial. Acquired resistance, an inevitability in targeted therapy, is expected to emerge through several mechanisms, including secondary KRAS mutations, bypass pathway activation through EGFR, HER2, or the PI3K–AKT–mTOR axis, adaptive upregulation of downstream effectors such as RAF or MEK, and tri-complex disruption via RAS Y64 or RAS Y71/BRAF alterations. Research to delineate these escape routes is already underway, and combination strategies — pairing daraxonrasib with chemotherapy, immunotherapy, or other targeted agents — will be critical to sustaining durable responses.

The broader RAS-targeted landscape is also evolving rapidly. Clinical trials of KRAS G12D-specific inhibitors, including VS-7375 and setidegrasib, are actively recruiting patients, and the strategic relationship between pan-RAS inhibitors covering multiple isoforms and mutants and allele-specific agents targeting a single variant — whether complementary or competitive — will be one of the defining questions of the coming years. What is no longer in dispute is the central lesson of this moment. RAS was long regarded as the holy grail of undruggable targets, a protein that defied every attempt at pharmacological conquest. Daraxonrasib has demonstrated that this target is not only tractable but capable of delivering tangible survival benefits and quality-of-life improvements to the patients who need them most. For the oncologists and surgeons who have long confronted the most recalcitrant of malignancies, the concurrent arrival of these two landmark studies marks the formal entry of pancreatic cancer therapeutics into the RAS-targeted era — a long-awaited dawn that has, at last, broken.

Subject of Research: Pan-RAS(ON) multi-selective inhibitor daraxonrasib as second-line therapy for RAS-mutated metastatic pancreatic ductal adenocarcinoma

Article Title: The dawn of RAS-targeted therapy: a landmark breakthrough of daraxonrasib in pancreatic cancer

Article References: Liu, C., & Liu, L. (2026). The dawn of RAS-targeted therapy: a landmark breakthrough of daraxonrasib in pancreatic cancer. Clinical Cancer Bulletin, 5(1), Article 20. https://doi.org/10.1007/s44272-026-00072-4

Image Credits: AI Generated

DOI: 10.1007/s44272-026-00072-4

Keywords: pancreatic cancer, daraxonrasib, RAS-targeted therapy, KRAS mutations, RASolute 302, targeted therapy, clinical trial, oncology, drug resistance, second-line treatment, molecular inhibition, precision medicine

Copper is an indispensable trace element, serving as a cofactor for enzymes involved in respiration, antioxidant defense, and connective tissue formation. Yet when copper homeostasis collapses, the consequences for a cell can be fatal in a way that scientists only began to define in 2022. That year, Peter Tsvetkov and colleagues reported in Science that excess mitochondrial copper binds directly to lipoylated components of the tricarboxylic acid cycle, the enzymatic engine at the heart of mitochondrial metabolism. The resulting accumulation of lipoylated TCA cycle proteins triggers a distinctive form of proteotoxic stress that the authors named cuproptosis, setting it apart from apoptosis, necrosis, and other better-known death programs. Crucially, the process depends on the mitochondrial protein ferredoxin 1, or FDX1, which regulates protein lipoylation through its interaction with the lipoic acid synthase LIAS.

What makes this mechanism so intriguing for liver cancer is a biological paradox. Hepatocellular carcinoma cells frequently exhibit elevated copper metabolism, importing and distributing the metal aggressively to fuel their proliferative demands. But the same dependence appears to raise their vulnerability: when copper overload is pharmacologically forced into the mitochondria, these copper-hungry cells die disproportionately. Earlier work from Tsvetkov’s group had shown that highly lipoylated, mitochondria-rich tumors are especially sensitive to elesclomol, an investigational copper ionophore that ferries copper ions into the mitochondrial interior. Disulfiram, an old alcohol-aversion drug that acts as a copper ionophore, has shown similar copper-dependent toxicity against tumor cells in multiple preclinical models, and recent studies have linked DLAT, a lipoylated enzyme of the pyruvate dehydrogenase complex, to elesclomol sensitivity specifically in hepatocellular carcinoma.

The iron side of the equation is equally consequential. Ferroptosis, first described in 2012, is a form of regulated cell death driven by iron-dependent lipid peroxidation. When the antioxidant systems that normally reduce lipid hydroperoxides falter, particularly the glutathione–glutathione peroxidase 4, or GSH–GPX4, axis, polyunsaturated fatty acids in cellular membranes undergo a radical chain reaction that ruptures the lipid bilayer. The liver, as the body’s principal iron storage and metabolic organ, is exquisitely sensitive to this chemistry. Hepatocellular carcinoma cells, meanwhile, must constantly manage iron influx and oxidative stress to survive, and numerous studies have documented that manipulating iron availability, lipid composition, and antioxidant capacity can tip these cells into ferroptotic death.

The review pays particular attention to the regulatory networks that determine how sensitive a given hepatocellular carcinoma cell is to ferroptosis. Nuclear factor erythroid 2–related factor 2, or NRF2, a master transcriptional regulator of antioxidant responses, emerges as a central node. When NRF2 signaling is active, cells upregulate glutathione synthesis, iron efflux, and a battery of cytoprotective enzymes, effectively raising a shield against lipid peroxidation. FSP1, a ferroptosis suppressor protein that reduces coenzyme Q10 at the plasma membrane, provides a parallel rescue pathway that operates independently of glutathione. Both defenses can be subverted: work from Ren and colleagues showed that overcoming the compensatory elevation of NRF2 rendered hepatocellular carcinoma cells markedly more vulnerable to disulfiram/copper-induced ferroptosis, while other studies have demonstrated that blocking the cystine transporter xCT, which feeds glutathione synthesis, cooperates lethally with copper-driven stress.

It is at this intersection that the review’s central thesis emerges. Copper toxicity and ferroptosis are not isolated programs; they converge on shared metabolic vulnerabilities. Mitochondrial copper overload destabilizes iron-sulfur clusters, the ancient cofactors that support respiratory and repair enzymes, and this destabilization can itself sensitize cells to lipid peroxidation through iron regulatory proteins. More strikingly, glutathione sits at the crossroads of both pathways. The antioxidant tripeptide neutralizes copper-driven oxidative stress on one hand and fuels GPX4-mediated suppression of ferroptosis on the other. Experimental studies in primary liver cancer have shown that ferroptosis inducers enhance cuproptosis triggered by copper ionophores, and that disulfiram/copper treatment consumes glutathione in a way that launches what one team described as a cascade of ferroptosis and cuproptosis when xCT compensation is simultaneously blocked.

The therapeutic implications are substantial. Standard first-line drugs for advanced hepatocellular carcinoma, including sorafenib and lenvatinib, already exert part of their activity through ferroptosis-related mechanisms; lenvatinib, for example, has been shown to induce ferroptosis via fibroblast growth factor receptor-4 inhibition, while sorafenib sensitivity is modulated by metallothioneins and antioxidant pathways. Layering copper ionophores on top of these agents could push tumor cells past a metabolic tipping point that single-agent therapy never reaches. Nanotechnology is accelerating this vision: research groups have developed reactive oxygen species–responsive nanoparticles co-delivering elesclomol and copper together with anti–PD-L1 immunotherapy, as well as injectable hydrogel systems that combine cuproptosis induction with stemness inhibition to overcome lenvatinib resistance. A 2026 study in Antioxidants described a ROS-responsive nanoplatform that targets both cuproptosis and ferroptosis for synergistic therapy against hepatocellular carcinoma, illustrating how rapidly the dual-targeting concept is moving from theory toward experimental implementation.

The tumor microenvironment adds a further dimension of complexity, and opportunity. Both cuproptosis and ferroptosis are immunologically loud forms of cell death: dying cells release damage-associated molecular patterns and oxidized lipids that can stimulate antitumor immunity, and vaccination with early ferroptotic cancer cells has been shown to induce efficient antitumor immune responses. Multiomics and single-cell sequencing analyses have linked cuproptosis signatures to the immunosuppressive architecture of tumors, while ferroptotic tumor cells can enhance the efficacy of checkpoint inhibitors. Yet the picture is not uniformly favorable. Some work has found that disulfiram combined with copper stabilizes PD-L1 in hepatocellular carcinoma, potentially inducing immunosuppression, a reminder that metal-based therapies must be calibrated carefully if they are to synergize with, rather than undermine, immunotherapy. Macrophage polarization, exosome-mediated signaling, and the metabolic state of stromal cells all modulate how these death programs play out in vivo.

The review’s authors are candid about the limits of the current evidence. Direct clinical data demonstrating that pharmacological induction of cuproptosis, or coordinated cuproptosis–ferroptosis targeting, benefits patients with hepatocellular carcinoma are still lacking. Copper chelation trials, trientine-based antiangiogenic strategies, and disulfiram repurposing efforts have generated encouraging preclinical signals, but translating them into validated regimens will require careful attention to dosing, copper delivery, and patient selection. Biomarkers are an urgent need: serum copper, zinc, and metallothionein levels have been proposed as potential biomarkers for hepatocellular carcinoma, and gene-expression signatures built around FDX1, DLAT, ATP7A, and other cuproptosis-related genes are being explored for prognostic and predictive value. Determining which tumors are copper-vulnerable, which rely on NRF2 or FSP1 for ferroptosis resistance, and which harbor metabolic contexts that favor one death program over the other will be essential for rational combination therapy.

Even with these caveats, the synthesis marks a conceptual shift in how liver cancer might be treated. Rather than viewing copper and iron merely as nutrients that tumors consume, the field increasingly regards their homeostatic control as a pair of interlocking kill switches. Disrupting mitochondrial copper handling destabilizes the metabolic core of the cell; dismantling antioxidant defenses unleashes iron-catalyzed membrane destruction; and because glutathione and related systems guard against both threats simultaneously, a single well-designed intervention can pull two levers at once. With combination strategies already showing synergy in preclinical liver cancer models, and nanoparticle delivery platforms maturing quickly, the copper–iron crosstalk framework offers hepatocellular carcinoma research one of its most mechanistically grounded and therapeutically tantalizing frontiers in years.

Subject of Research: Cuproptosis and ferroptosis as coordinated therapeutic targets in hepatocellular carcinoma

Article Title: Harnessing copper-iron crosstalk: A novel strategy to combat hepatocellular carcinoma

Article References: Xie, X., Cao, H., Chen, H., Zhang, S., & Han, Z. (2026). Harnessing copper-iron crosstalk: A novel strategy to combat hepatocellular carcinoma. Medical Oncology, 43(10), Article 268. https://doi.org/10.1007/s12032-026-03399-z

Image Credits: AI Generated

DOI: 10.1007/s12032-026-03399-z

Keywords: cuproptosis, ferroptosis, hepatocellular carcinoma, copper metabolism, iron metabolism, GPX4, NRF2, FDX1, disulfiram, elesclomol, glutathione, targeted therapy

The appeal of MOFs begins with their architecture. Metal centers or clusters act as nodes, joined by organic linkers into extended three-dimensional crystalline networks whose pores can be adjusted with near-atomic precision. Because researchers can independently vary the metal, the linker and the functional groups decorating the pore walls, MOFs offer record-breaking internal surface areas, tunable pore sizes and a modular versatility that rigid inorganic adsorbents such as zeolites struggle to match. The review categorizes frameworks into rigid structures suited to molecular sieving, flexible or breathing frameworks whose unit cells expand and contract as guest molecules enter and leave, and surface-functionalized frameworks grafted with groups such as amines, sulfonates or carboxylates that dramatically alter adsorption affinity, hydrophobicity and stability. Open metal sites, generated when coordinated solvent molecules are stripped away during activation, add another handle for tuning performance; the copper framework HKUST-1, for example, adsorbs notably more carbon dioxide in the presence of a small amount of water.

A substantial portion of the review is devoted to how these materials are actually made, because the synthesis route shapes everything from crystallinity to cost. Solvothermal and hydrothermal methods remain the workhorses, producing highly crystalline frameworks such as MIL-101(Cr) and UiO-66, but they demand high temperatures and pressures, large volumes of organic solvents and long reaction times that limit scalability. Microwave-assisted synthesis slashes reaction times and yields uniform nanocrystals with high phase purity, yet scaling microwave equipment to industrial throughput is difficult. Sonochemistry accelerates nucleation with cavitation bubbles that momentarily reach thousands of kelvin, producing nanoscale MOFs with high surface areas, though controlling particle size distribution remains a challenge. Mechanochemical routes grind metal salts and linkers together in ball mills with little or no solvent, offering a genuinely green option at room temperature, at the cost of somewhat lower crystallinity. Electrochemical synthesis, first used by BASF to make HKUST-1 in 2005, supplies metal ions through anodic dissolution of a metal electrode, avoiding corrosive counterions and enabling continuous production. The authors conclude that no method is universally ideal: high crystallinity and tunability favor solvothermal chemistry, while green scalability increasingly points toward mechanochemical and continuous-flow techniques.

In the environmental arena, the review highlights MOFs as adsorbents and catalytic degradation platforms for three major classes of pollutants: synthetic dyes, heavy metals and emerging contaminants. Dye pollution is a serious concern because many residual dyes are carcinogenic and persist in water systems. Frameworks from the UiO, ZIF and MIL families, along with their composites, capture both cationic dyes such as methylene blue, rhodamine B and malachite green and anionic dyes such as methyl orange and congo red. The removal mechanisms operate in synergy: electrostatic attraction between oppositely charged dye molecules and framework surfaces, pi–pi stacking between the aromatic rings of dyes and the organic linkers, hydrogen bonding between surface functional groups and dye molecules, and size-selective pore filling. Because the surface charge of a MOF depends on solution pH and the functional groups present, researchers can engineer adsorbents that switch selectivity simply by decorating the pore walls.

Heavy metals present an even sterner test because they are non-biodegradable and toxic at low concentrations. MOFs bind Pb(II), Cr(VI), As(III/V) and Hg(II) through a combination of ion exchange, surface complexation, chelation, electrostatic interaction and redox conversion. Functionalization with thiol or amine groups markedly boosts selectivity for soft, highly toxic ions such as Hg(II), while redox-active iron-based frameworks can reduce toxic Cr(VI) to the far less hazardous Cr(III), coupling detoxification with immobilization. The review also emphasizes MOF-based membranes, formed when MOF crystals self-assemble on porous supports, which combine tunable pore sizes with high selectivity and recyclability for continuous water purification. The trade-offs are candidly acknowledged: MIL-101(Cr) offers enormous mesoporous cages that handle bulky dye and pharmaceutical molecules, but zirconium-based UiO-66 provides superior chemical robustness, and ZIF-8 resists water yet suffers from narrow pore apertures that restrict diffusion of large contaminants.

The second half of the review turns to biomedicine, where the requirements are far stricter than in industrial applications. An effective MOF drug carrier must encapsulate therapeutics at high loading, degrade in a controlled manner, release its cargo on demand, present acceptable toxicology and lend itself to surface engineering that dictates its fate in the body. MOFs meet these criteria in ways that conventional carriers such as liposomes, mesoporous silica and polymeric nanoparticles often cannot: their surface areas permit exceptionally high drug loading, pores of up to six nanometers accommodate molecules ranging from small-molecule drugs to peptides and large biomolecules, and their relatively weak coordination bonds allow the framework to decompose harmlessly and release its components. Loading can be achieved by diffusion into preformed crystals, by covalent attachment to the external surface, by in situ encapsulation during synthesis, or by using the drug itself as a ligand in framework construction.

Concrete examples illustrate the promise. A chiral zinc-based framework built from triazine-triisophthalate linkers absorbed the anticancer drug 5-fluorouracil through hydrogen bonding at a loading of 0.5 grams per gram and released it slowly over a week in buffered saline. In antibacterial applications, the iron framework MIL-53(Fe) physically loaded the glycopeptide antibiotic vancomycin to nearly 20 percent by weight and, under the acidic conditions that mimic a bacterial infection, released it in a controlled fashion that achieved 99.3 percent efficacy against Staphylococcus aureus while remaining biocompatible in vitro. ZIF-8 has been used to ferry the broad-spectrum cephalosporin ceftazidime, confirmed by element mapping in electron microscopy, and to co-deliver doxorubicin with the P-glycoprotein inhibitor verapamil in folate-targeted, PEG-coated particles that overcame multidrug resistance in tumor cells. A biomimetic nanoreactor combining ZIF-8 with the prodrug tirapazamine, the enzyme glucose oxidase and an erythrocyte membrane coating points toward cancer starvation therapy with improved delivery.

The range of biomedical uses continues to broaden. Copper nanowires sheathed in ZIF-8 slowed the release of antiviral copper ions, showed low cytotoxicity with 99 percent of kidney cells surviving after 48 hours, and were investigated against SARS-CoV-2 in infected cells; surface-functionalized MOFs bearing nystatin, folic acid or tenofovir can bind viral capsid proteins and immobilize viruses. Copper–BTC films grown directly on stent surfaces catalyze the production of nitric oxide from blood-borne s-nitroso-cysteine, improving blood compatibility, while MOF–polymer coatings have been shown to inhibit bacterial attachment to medical tubing under flow. Frameworks delivering ibuprofen to reduce brain inflammation or dopamine for neurological therapy, along with ATP-responsive zirconium systems, extend the concept into chronic disease management, although crossing the blood–brain barrier remains a formidable hurdle.

The review is refreshingly blunt about the obstacles that stand between laboratory success and clinical or industrial deployment. MOF toxicity, driven by metal ion release, particle size, shape and aggregation, can produce oxidative stress, inflammation and organ damage, and standardized toxicity testing protocols and long-term in vivo biocompatibility data are still lacking. Water stability in real treatment streams, biodegradability in physiological settings, regeneration and reuse of adsorbents, material costs and the reproducibility of green synthesis routes all demand further work. Compared with clinically established liposomes and hydrogels, MOFs carry biosafety uncertainty and more complex, expensive synthesis. Yet the trajectory is clear. With defect engineering, biocompatible metal choices, scalable continuous-flow production and rational linking of synthesis conditions to structure–performance relationships, the authors argue, these crystalline cages could become central platforms for sustainable water purification and personalized medicine alike, addressing some of the most pressing environmental and health challenges of the coming decades.

Subject of Research: Metal–organic frameworks for wastewater treatment and targeted drug delivery

Article Title: Emerging roles of metal organic frameworks in wastewater treatment and targeted drug delivery applications

Article References: Singh, P., Singh, G., Singh, C. K., Nitin, V., & Sodhi, K. K. (2026). Emerging roles of metal organic frameworks in wastewater treatment and targeted drug delivery applications. Discover Industrial Chemistry and Materials, 1(1), Article 12. https://doi.org/10.1007/s44508-026-00010-1

Image Credits: AI Generated

DOI: 10.1007/s44508-026-00010-1

Keywords: metal–organic frameworks, MOF synthesis, wastewater treatment, heavy metal adsorption, dye removal, drug delivery, targeted cancer therapy, biocompatibility, MOF membranes, stimuli-responsive release, antibacterial agents, water purification

Triple-negative breast cancer, or TNBC, accounts for a disproportionate share of breast cancer deaths worldwide. Unlike other breast cancers, TNBC cells lack estrogen receptors, progesterone receptors, and excess HER2 protein, the three molecular targets that drive most modern breast cancer therapies. That absence means patients cannot benefit from hormone therapy or HER2-directed drugs, leaving chemotherapy as the main systemic option. The result is high malignancy, an elevated risk of recurrence and metastasis, and limited therapeutic choices. Against this backdrop, the search for compounds that can eliminate TNBC cells through novel mechanisms has become a pressing priority in oncology research.

The compound at the center of the new study belongs to the Schiff base family, a class of organic molecules formed through a condensation reaction first characterized by Hugo Schiff in 1864. Schiff bases contain an imine functional group, a carbon-nitrogen double bond, and have long been prized in medicinal chemistry for their structural versatility and biological activity. VALD-3 itself is a derivative synthesized from o-vanillin, and it is not entirely new to cancer researchers. Earlier work showed that VALD-3 can induce cell cycle arrest and apoptosis in breast cancer cells by inhibiting the Wnt/β-catenin pathway, and separate studies found it suppresses colorectal cancer cells by upregulating the tumor suppressor p53. The new research, however, uncovers a far more dramatic mode of action.

When the research team, led by Xuhui Zhao of Gansu Provincial Hospital in Lanzhou and including collaborators from Northwest Normal University, exposed breast cancer cells to VALD-3 in the laboratory, they observed cytotoxic effects on both TNBC cells and estrogen receptor-positive MCF-7 cells. Crucially, however, the compound was significantly more potent against the triple-negative cells. And the way those cells died was anything but ordinary. Under the microscope, the cells displayed the unmistakable hallmarks of pyroptosis: they swelled dramatically, sprouted balloon-like protrusions from their membranes, and eventually burst, releasing a flood of inflammatory cytokines into their surroundings.

Pyroptosis is a relatively recent addition to the catalog of programmed cell death. Long familiar as apoptosis, the quiet, orderly suicide of cells, biologists have increasingly recognized that cells can also die in a much louder fashion. First described in immune cells infected by bacteria, pyroptosis is a form of inflammatory programmed cell death in which pores form in the plasma membrane, causing the cell to swell, rupture, and spill its pro-inflammatory contents. The gasdermin family of proteins provides the execution machinery. When a gasdermin protein is cleaved, its pore-forming domain is unleashed, punching holes in the cell membrane. One member of this family, gasdermin E, or GSDME, has attracted particular attention because it can convert the apoptotic program into pyroptosis: caspase-3, the central executioner of apoptosis, can cleave GSDME, transforming a silent death into an explosive one. Intriguingly, GSDME has also been shown to suppress tumor growth by activating anti-tumor immunity, which makes inducing GSDME-dependent pyroptosis an attractive strategy in cancer therapy.

The mechanistic detective work in the new study traced a clear signaling cascade from the initial drug exposure to the final rupture of the cell membrane. The first domino to fall was reactive oxygen species, or ROS. VALD-3 treatment caused ROS levels inside TNBC cells to climb. Far from being mere metabolic noise, ROS at high levels act as potent signaling molecules, particularly within the mitochondria, the energy-producing organelles that are also central arbiters of cell death decisions. Excessive mitochondrial ROS is a well-established trigger of apoptotic signaling, and many anticancer agents exploit precisely this vulnerability.

The rising ROS levels in turn drove the phosphorylation of JNK, a stress-activated protein kinase that relays oxidative stress signals to the mitochondrial machinery. Activated JNK promoted the recruitment of Bax, a pro-apoptotic member of the Bcl-2 protein family, to the outer mitochondrial membrane. There, Bax formed a heterodimer with Bcl-2, the family’s signature anti-apoptotic protein, effectively neutralizing the cell’s principal defense against self-destruction. With Bax entrenched on the mitochondria and Bcl-2 sequestered, the outer mitochondrial membrane became permeable, and cytochrome c, a protein normally tucked away in the space between the mitochondrial membranes, spilled into the cytoplasm. This release is the classic point of no return in the intrinsic apoptotic pathway.

Once in the cytoplasm, cytochrome c set in motion the activation of caspase-3, the protease that dismantles the cell from within. But here the story took its decisive turn. Instead of ending quietly in apoptosis, the activated caspase-3 cleaved gasdermin E. The cleaved GSDME fragments migrated to the plasma membrane and began forming pores, producing the swelling, ballooning, and inflammatory rupture that the researchers had observed. In other words, VALD-3 hijacked the standard apoptotic machinery and diverted it into pyroptosis, initiating the ROS/JNK/Bax-mitochondrial apoptosis pathway and culminating in caspase-3 activation and GSDME cleavage. The result was the complete eradication of the cancer cells through a mechanism that simultaneously recruits the immune system to the tumor site.

Perhaps the most clinically tantalizing observation is the selectivity of this process. Although VALD-3 was toxic to both TNBC and ER-positive MCF-7 cells, the characteristic pyroptotic features emerged selectively in the triple-negative cells. This preferential induction of pyroptosis in the harder-to-treat subtype suggests that TNBC cells may be especially vulnerable to this form of death, or that their GSDME expression and mitochondrial stress responses make them uniquely susceptible to the ROS-driven cascade. Either way, the specificity offers a potential therapeutic window: a treatment that devastates TNBC cells while sparing mechanisms that might fuel inflammation-driven progression in other tumor contexts.

The study is not the first to connect ROS-driven stress to GSDME-dependent pyroptosis in TNBC. Tetraarsenic hexoxide, for example, has been reported to promote pyroptosis in these cells through mitochondrial ROS generation and caspase-3/GSDME activation, and triclabendazole, a veterinary anthelmintic, has been shown to activate the same caspase-3/GSDME axis in breast cancer cells. What distinguishes the new work is both the identity of the agent, a rationally designed Schiff base derivative with a growing portfolio of anticancer activity, and the completeness of the pathway map, which connects ROS production through JNK phosphorylation, Bax mitochondrial recruitment, Bcl-2 sequestration, cytochrome c release, and caspase-3 activation all the way to GSDME cleavage and membrane rupture.

The researchers, based at Gansu Provincial Hospital, The First People’s Hospital of Longxi County, and Northwest Normal University, also tested the compound’s effects on tumor growth in vivo, reporting that VALD-3 treatment inhibited tumor growth, consistent with the pyroptotic cell death observed in culture. The work was funded by the Natural Science Foundation of China and several Gansu provincial research programs, reflecting a concerted effort to develop locally synthesized chemical entities into credible anticancer candidates.

There are, of course, substantial hurdles between a laboratory observation and a clinical therapy. Pyroptosis is a double-edged sword: the inflammatory cytokines released by dying cells can stimulate anti-tumor immunity, but excessive inflammation can also cause tissue damage and, in some contexts, promote tumor progression. Researchers will need to establish careful dosing strategies, verify the selectivity in normal tissues, and determine whether GSDME expression levels in patient tumors can serve as a biomarker to identify who would benefit most from such treatment. The safety profile of VALD-3 in humans remains entirely untested.

Even so, the study adds a compelling entry to the expanding repertoire of pyroptosis-inducing anticancer strategies and offers a new mechanistic explanation for the activity of a compound that researchers have been probing for years. For patients with triple-negative breast cancer, whose options remain constrained by the biology of their disease, the prospect of a small molecule that converts the cancer cell’s own death machinery into an immune-activating fire alarm is a reason for cautious optimism. The findings suggest that GSDME-dependent pyroptosis is a novel mechanism by which VALD-3 eradicates cancer cells, and they offer new insights into potential clinical applications for anticancer therapies aimed at the most aggressive form of breast cancer.